The effect of CYP2C19 polymorphism on the pharmacokinetics and pharmacodynamics of clopidogrel: a possible mechanism for clopidogrel resistance

• Published in: Clinical pharmacology and therapeutics Vol. 84; no. 2; p. 236
• Main Authors: Kim, K A, Park, P W, Hong, S J, Park, J-Y
• Format: Journal Article
• Language: English
• Published: United States 01.08.2008
• Subjects: Adult; Area Under Curve; Aryl Hydrocarbon Hydroxylases - genetics; Blood Platelets - drug effects; Cytochrome P-450 CYP2C19; Drug Administration Schedule; Drug Resistance - genetics; Female; Genotype; Humans; Korea; Male; Platelet Aggregation Inhibitors - administration & dosage; Platelet Aggregation Inhibitors - blood; Platelet Aggregation Inhibitors - pharmacokinetics; Platelet Aggregation Inhibitors - pharmacology; Polymorphism, Genetic; Ticlopidine - administration & dosage; Ticlopidine - analogs & derivatives; Ticlopidine - blood; Ticlopidine - pharmacokinetics; Ticlopidine - pharmacology

We evaluated the effect of the CYP2C19 genotype on the pharmacokinetics and pharmacodynamcis of clopidogrel. Twenty-four subjects were divided into three groups on the basis of their CYP2C19 genotype: homozygous extensive metabolizers (homoEMs, n = 8), heterozygous EMs (heteroEMs, n = 8), and poor m...